Omnicell, Inc. (NASDAQ:OMCL) Receives $52.33 Average Price Target from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average recommendation of “Hold” by the six research firms that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $52.33.

Several equities research analysts recently weighed in on the stock. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Barclays increased their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st.

Insider Activity at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Pier Capital LLC acquired a new stake in Omnicell in the third quarter worth approximately $5,859,000. Royce & Associates LP acquired a new stake in shares of Omnicell in the third quarter valued at $811,000. Geode Capital Management LLC boosted its stake in Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after buying an additional 2,877 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Omnicell by 750.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after acquiring an additional 259,463 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Omnicell in the third quarter worth about $753,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Up 0.2 %

Shares of NASDAQ:OMCL opened at $39.72 on Monday. The stock has a 50-day simple moving average of $42.96 and a 200-day simple moving average of $43.86. The stock has a market capitalization of $1.84 billion, a P/E ratio of 147.12, a PEG ratio of 7.53 and a beta of 0.78. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts forecast that Omnicell will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.